- Home
- TOPS vs IGC Comparison
TOPS vs IGC Comparison
Compare TOPS & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- IGC
- Stock Information
- Founded
- TOPS 2000
- IGC 2005
- Country
- TOPS Greece
- IGC United States
- Employees
- TOPS N/A
- IGC N/A
- Industry
- TOPS Marine Transportation
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- IGC Health Care
- Exchange
- TOPS Nasdaq
- IGC Nasdaq
- Market Cap
- TOPS 28.3M
- IGC 29.4M
- IPO Year
- TOPS 2004
- IGC N/A
- Fundamental
- Price
- TOPS $6.12
- IGC $0.31
- Analyst Decision
- TOPS
- IGC Strong Buy
- Analyst Count
- TOPS 0
- IGC 2
- Target Price
- TOPS N/A
- IGC $3.75
- AVG Volume (30 Days)
- TOPS 10.1K
- IGC 374.0K
- Earning Date
- TOPS 03-28-2025
- IGC 02-12-2025
- Dividend Yield
- TOPS N/A
- IGC N/A
- EPS Growth
- TOPS N/A
- IGC N/A
- EPS
- TOPS N/A
- IGC N/A
- Revenue
- TOPS $83,870,000.00
- IGC $1,183,000.00
- Revenue This Year
- TOPS $7.10
- IGC N/A
- Revenue Next Year
- TOPS $6.54
- IGC $13.38
- P/E Ratio
- TOPS N/A
- IGC N/A
- Revenue Growth
- TOPS 1.10
- IGC N/A
- 52 Week Low
- TOPS $5.30
- IGC $0.27
- 52 Week High
- TOPS $14.94
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- TOPS 35.63
- IGC 37.57
- Support Level
- TOPS $6.11
- IGC $0.31
- Resistance Level
- TOPS $6.44
- IGC $0.37
- Average True Range (ATR)
- TOPS 0.39
- IGC 0.02
- MACD
- TOPS -0.07
- IGC -0.00
- Stochastic Oscillator
- TOPS 2.29
- IGC 18.18
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The company focuses on the transportation of petroleum products (clean and dirty) and bulk liquid chemicals. The Company is an international provider of worldwide oil, petroleum products and chemical transportation services. It generates revenue from the Time Charter agreements.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.